Description
Product Usage Information
Western Blotting: 1:1000
Simple Western™: 1:10 - 1:50
Immunohistochemistry (Paraffin): 1:800 - 1:3200
Storage
Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/mL BSA, 50% glycerol, and less than 0.02% sodium azide. Store at -20°C. Do not aliquot the antibody.
Protocol
Available protocols: Western Blotting, Immunohistochemistry (Paraffin)
Specificity / Sensitivity
ADAR2 (F6U8S) Rabbit Monoclonal Antibody recognizes endogenous levels of total ADAR2 protein. This antibody detects a non-specific band of unknown origin at 180 kDa that might represent the ADAR2 homodimer.
Species Reactivity: Human, Mouse, Rat, Monkey
Source / Purification
Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the carboxy terminus of human ADAR2 protein.
Background
ADAR2, also known as RED1, is an enzyme that catalyzes the adenosine (A) to inosine (I) editing of double-stranded RNA (dsRNA) (1). This is the most common type of RNA editing in mammals, and because inosine is read as guanosine by the cellular machinery, ADAR2 can effectively alter genetic information at the RNA level (2,3). ADAR2 is known to be efficient and perform site-specific editing, thereby modulating encoded protein properties (4). ADAR2 can influence RNA stability by modifying the access of RNA-binding proteins, particularly decay-promoting factors (5), and has also been shown to affect alternative splicing (6). Importantly, ADAR2 forms a homodimer complex, which is critical for its functions (7,8). Dysregulation of ADAR2 activity has been implicated in various human diseases, including amyotrophic lateral sclerosis (ALS), where reduced ADAR2-mediated editing of GluA2, a subunit of the L-α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor, has been observed (9). ADAR2 has also been linked to cancer, with altered ADAR2 expression correlating with malignancy in different tumor types. ADAR2 also edits numerous miRNAs and contributes to tumorigenesis regulation by balancing the functions of oncogenic and tumor-suppressive miRNAs (10,11). ADAR2 can also display tumor-suppressive functions. For example, ADAR2 is downregulated in approximately 50% of hepatocellular carcinoma (HCC), and overexpression of ADAR2 in ADAR-deficient HCC cells reduces their oncogenic potential (12).
Alternate Names
ADAR2; ADARB1; adenosine deaminase RNA specific B1; adenosine deaminase, RNA-specific, B1 (homolog of rat RED1); adenosine deaminase, RNA-specific, B1 (RED1 homolog rat); Double-stranded RNA-specific editase 1; DRABA2; DRADA2; dsRNA adenosine deaminase; dsRNA adenosine deaminase DRADA2; human dsRNA adenosine deaminase DRADA2; NEDHYMS; RED1; RNA editase; RNA editing deaminase 1; RNA-editing deaminase 1; RNA-editing enzyme 1
